advances of pd-1/pd-l1 inhibitors in tumor immunotherapy

Clicks: 350
ID: 247999
2017
Free PDF
Article Quality & Performance Metrics
Overall Quality
Not rated
Combines reader engagement with the AI quality analysis. This article has not been analysed, so there is no overall score — reader engagement is measured and shown alongside.
AI Quality Assessment
Not analyzed
Readership in this journal
Steady

Ranked #7 of 12 articles by views in The American journal of forensic medicine and pathology

Most read Least read

Bar heights use a square-root scale.

Mint this article as an NFT
Not yet minted

Create a permanent, verifiable on-chain record of this article on the Scimatic Network. The NFT is held in your Journament account, and you can withdraw it to your own wallet at any time.

5 SUSD one-off · no wallet required
Sign in to mint
Abstract
Tumor immunotherapy, as one of the most promising research directions in the present field of oncotherapy, inhibits and kills tumor cells by enhancing anti-tumor immunity of the body. PD-1/PD-L1 inhibitors block negative control signals by inhibiting binding of PD-1 to its ligand PD-L1, leading to recovery of T cell activity and enhancement of immune response. In recent years, PD-1/PD-L1 inhibitors have shown good therapeutic effects in multiple tumor immunotherapies, making patients obtain long-term tumor remission and with controlled toxic and side effects. This article mainly reviewed the action mechanism and current situation of PD-1/PD-L1 inhibitors as well as their application effects in the treatment of various tumors.
Reference Key
liu2017journaladvances Use this key to autocite in the manuscript while using SciMatic Manuscript Manager or Thesis Manager
Authors ;Yong-jun LIU;Yan ZHOU
Journal The American journal of forensic medicine and pathology
Year 2017
DOI
10.11910/2227-6394.2017.05.02.05
URL
http://www.jitm.hk/EN/abstract/abstract245.shtml
Keywords
pd-l1 pd-1 tumor immunotherapymedicine

Citations

No citations found. To add a citation, contact the admin at info@scimatic.org

Comments

No comments yet. Be the first to comment on this article.